Sunitinib Malate (CAS 341031-54-7) Suppliers and Product Information

Sunitinib Malate is a novel oral multi-targeted anticancer drug and belongs to the class of multi-targeted tyrosine kinase inhibitors. It is used for the treatment of gastrointestinal stromal tumors (GIST), advanced renal cell carcinoma (RCC), and advanced pancreatic endocrine tumors. The drug works by preventing tumor cells from obtaining blood and nutrients needed for growth, as well as directly attacking tumor cells.

Frequently Asked Questions about Sunitinib Malate

Q: What are the main indications for Sunitinib Malate?

A: Sunitinib Malate is indicated for: 1. Patients who failed in the treatment with imatinib mesylate or are intolerant to gastrointestinal stromal tumors (GIST) 2. Inoperable advanced renal cell carcinoma (RCC) 3. Advanced pancreatic endocrine tumors

Q: How does Sunitinib Malate work?

A: Sunitinib Malate works by inhibiting multiple receptor tyrosine kinases, including VEGFR2 (Flk-1), PDGFRβ, c-Kit, FLT3, RET, and CSF-1R. This results in slowing tumor progression and inhibiting angiogenesis, which is particularly useful in highly vascularized cancers like RCC and GIST.

Q: What are the common side effects of Sunitinib Malate?

A: Common adverse effects of Sunitinib Malate include fatigue, diarrhea, yellow skin discoloration, anorexia, nausea, and mucositis. Mild myelosuppression has been reported in some patients, including neutropenia, lymphopenia, thrombocytopenia, and anemia. There have also been reports of cardiotoxicity, including decreases in left ventricular ejection fraction.